A Review of the Effectiveness of Homoeoprophylaxis: SARS-CoV-2 Compared to Pre-COVID-19 Infectious Diseases

Abstract

From Hahnemann's use in 1799 of Belladonna 30 to prevent scarlet fever, to the prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2023, appropriate potencies of similarly 'similar' remedies have been used to prevent targeted infectious diseases. This is known to many as homeoprophylaxis (HP) or 'similar prevention.' Data from recent surveys suggest that the effectiveness of HP remedies against SARS-CoV-2 is lower compared to other infectious diseases. This review examines relevant evidence and suggests possible explanations for the emerging difference and ways to improve HP effectiveness. Evidence of HP's effectiveness against a range of infectious diseases from 1974 to 2014 is compared with evidence of HP's effectiveness against SARS-CoV-2 collected from 2020 to 2022. A summary of the evidence, describing the use of over 247,000,000 doses of HP medicines against various infectious diseases, suggests an average effectiveness of around 88%. Another summary of the evidence, describing the use of HP by several authors in 2020, 2021, and 2022 against SARS-CoV-2, shows a range of effectiveness around 70%. The reasons for apparent differences in HP effectiveness between 'traditional' infectious diseases and SARS-CoV-2 are discussed. It is suggested that these differences could have been expected, particularly due to the quality of most nosodes against SARS-CoV-2. The value of HP in comparison to coronavirus disease 2019 vaccines is also discussed, and conclusions are drawn. Appropriate HP against SARS-CoV-2 offers an option that appears to be at least as effective as vaccination, without any risk of toxic damage, but there is room for improvement.

Keywords

homoeoprophylaxis - immunisation - effectiveness - infectious diseases - SARS-CoV-2

Publication History

Article published online:
07 December 2023

• References

• 1 Hahnemann S. The Cure and Prevention of Scarlet Fever. Hahnemann's Lesser Writings . New Delhi: B Jain Publishers; 1987: 369-385
• 2 Burnett JC. Vaccinosis and Its Cure by Thuja; with Remarks on Homoeoprophylaxis. 2nd edition 1897.. New Delhi: B Jain Publishing; 1996: 95-97
• 3 Eaton CW. Variolinum. A paper read before the American Institute of Homeopathy. J Am Inst Homeopath 1907; 547-567
• 4 Golden I. Large homoeoprophylaxis: brief and long-term interventions. American Journal of Homeopathic Medicine 2019; 112 (01) 31-36
• 5 Golden I. Large homoeoprophylaxis interventions by government institutions. The Australian J Homeopathic Med 2019; 31 (02) 14-19
• 6 Golden I. 2021 Survey of prevention, treatment and detoxification options for SARS-CoV-2, shedding and vaccine injury – preliminary results. The Australian J Homeopathic Med 2022; 35 (02) 6-14
• 7 Golden I. 2022 Survey of prevention, treatment and detoxification options for SARS-CoV-2, shedding and vaccine injury – preliminary results. The Australian J Homeopathic Med 2023; 36 (01) 37-45
• 8 A direct control group is where the control is part of a single cohort where an intervention against a targeted disease is being studied, e.g., a HP and a non-HP group within the same city, or same region. An indirect control group is where a single disease is intervened within say one State or one suburb, and notifications and deaths from the disease are compared to those in other States or suburbs
• 9 A fall factor analysis compares the rates of decline in the incidence of a targeted infectious disease in different regions or different cohorts within one region. These rates can be plotted to show a simple visual comparison
• 10 The pre-2014 Cuban interventions are summarised in Bracho G, Golden I. A Brief History of Homeoprophylaxis in Cuba, 2004–2014. Homeopathic Links 2016; 29 (02) 128-134 Accessed October 23, 2023 at: https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0036-1583209
• 11 Rastogi DP, Sharma VD. Study of homoeopathic drugs in encephalitis epidemic (1991) in Uttar Pradesh (India). CCRH Quarterly Bulletin 1992; 14 (3–4): 1-11
• 12 CCRH. Dengue epidemic – scientific activities of Council. CCRH News 1996–97 (23) 10
• 13 Gadugu S, Nyapati SR. Sastry GLN. An open observational study on efficacy of miasmatic prescription in the prevention of Japanese Encephalitis. Homeopathy 2014; 103 (01) 78-79
• 14 Dr R. Rejikumar, Dr R S Dinesh et al. A Study on the Prophylactic Efficacy of Homoeopathic Preventive Medicine Against Chikungunya Fever. Accessed October 23, 2023 at: http://www.similima.com/pdf/efficacy-chiunguna-kerala.pdf
• 15 Government of Kerala. Protective Efficacy of “Genus Epidemicus” (Homeopathic Preventative) Administered During Epidemic Fever in Kerala. Accessed October 23, 2023 at: http://www.homoeopathy.kerala.gov.in/docs/jan2011/raech_report.pdf
• 16 Janardanan Nair KR. S. Gopinadhan S et al. Homoeopathic Genus Epidemicus 'Bryonia alba' as a prophylactic during an outbreak of Chikungunya in India: A cluster -randomised, double -blind, placebo- controlled trial. Indian J Research Homeopathy 2015
• 17 Castro and Nogiera. Use of the nosode Meningococcinum as a preventive against meningitis. J Am Inst Homeopath 1975; 68 (04) 211-219 https://www.austinclinicofhomeopathy.com/uploads/1/9/0/4/1904116/brazil_homeoprophylaxis.pdf
• 18 Mronisnski C, Adriano E, Mattos G. (1998/99) Meningococcinum: Its protective effect against Meningococcal disease, Homeopathic Links, Vol 14 Winter 2001, 230–234. Accessed October 23, 2023 at: https://ddata.over-blog.com/3/27/09/71/2012-2013/Juin-2013/Bresil–prevention-homeopathique-du-Meningocoque.pdf
• 19 Marino R. Homeopathy and collective health: the case of dengue epidemics. International Journal of High Dilution Research 2008; 7 (25) 179-185 https://pdfs.semanticscholar.org/2408/49a59ca38b583e8918598b56a75ea7f24d04.pdf
• 20 de Souza Nunes LA. Contribution of homeopathy to the control of an outbreak of dengue in Macaé, Rio de Janeiro. Int J High Dilution Res 2008; 7 (25) 186-192 https://web.archive.org/web/20230110224239/https://homeopathyplus.com/denguehomeopathy.pdf
• 21 Nunes LA. Dengue and Homeopathy: A Successful Experience from Macae. Accessed October 23, 2023 at: http://www.ecomedicina.com.br/site/conteudo/entrevista22.asp
• 22 Golden I. Large homoeoprophylaxis interventions by government institutions. Similia – . Aust J Homeopathic Med 2019; 31 (02) 16-17
• 23 Golden I. The Complete Practitioners Manual of Homoeoprophylaxis. Gisborne, Victoria, Australia: Isaac Golden Publications; 2012: 63-68
• 24 Golden I. The Potential Value of Homoeoprophylaxis in Endemic and Epidemic Conditions. Homeopathy 360. 1.4.2019. Accessed October 23, 2023 at: https://homeopathy360.com/2019/04/01/the-potential-value-of-homoeoprophylaxis-in-endemic-and-epidemic-conditions/
• 25 Bill Gates speaks to Rt Hon Jeremy Hunt MP in exclusive Policy Exchange interview. Accessed October 23, 2023 at: https://www.youtube.com/watch?v=CZplF4qdwII at 27:53 minutes. 15.11.21.
• 26 Lin D-Y, Xu Y, Gu Y. et al. Effectiveness of bivalent boosters against severe omicron infection. N Engl J Med 2023; 388 (08) 764-766
• 27 Offit PA. quoted in Imprinting, Expert Says—Paul Offit, MD, also argues that boosting should be reserved for older or vulnerable individuals. Medpage today. 12th January 2023. Accessed October 23, 2023 at: https://www.medpagetoday.com/infectiousdisease/covid19vaccine/102604